| Literature DB >> 27936019 |
Na Xing1, Xiaoxiao Guan1, Bin An1, Beibei Cui1, Zengguo Wang1, Xiaoya Wang1, Xiujuan Zhang1, Qian Du1, Xiaomin Zhao1, Yong Huang1, Dewen Tong1.
Abstract
Porcine epidemic diarrhea virus (PEDV) is the main causative agent of porcine diarrhea, which has resulted in devastating damage to swine industry and become a perplexed global problem. PEDV infection causes lesions and clinical symptoms, and infected pigs often succumb to severe dehydration. If there is not a timely and effective method to control its infection, PEDV will spread rapidly across the whole swine farm. Therefore, preclinical identification of PEDV is of great significance for preventing the outbreak and spread of this disease. In this study, a functionalized nanoparticles-based PCR method (UNDP-PCR) specific for PEDV was developed through systematic optimization of functionalized magnetic beads and gold nanoparticles which were further used to specifically enrich viral RNA from the lysate of PEDV stool samples, forming a MMPs-RNA-AuNPs complex. Then, oligonucleotides specific for PEDV coated on AuNPs were eluted from the complex and were further amplified and characterized by PCR. The detection limitation of the established UNDP-PCR method for PEDV was 25 copies in per gram PEDV stool samples, which is 400-fold more sensitive than conventional RT-PCR for stool samples. The UNDP-PCR for PEDV exhibited reliable reproducibility and high specificity, no cross-reaction was observed with other porcine viruses. In 153 preclinical fecal samples, the positive detection rate of UNDP-PCR specific for PEDV (30.72%) was much higher than that of conventional RT-PCR (5.88%) and SYBR Green real-time RT-PCR. In a word, this study provided a RNA extraction and transcription free, rapid and economical method for preclinical PEDV infection, which showed higher sensitivity, specificity and reproducibility, and exhibited application potency for evaluating viral loads of preclinical samples.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27936019 PMCID: PMC5147876 DOI: 10.1371/journal.pone.0167325
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers and selected probes used in this study.
| Label | Orientation | Assay | Sequence (5′–3′) | Position |
|---|---|---|---|---|
| pGL3-F | Forward | LINK-PCR | 58–77 | |
| pGL3-R | Reverse | LINK-PCR | 967–948 | |
| PEDVF | Forward | Conventional-PCR | 618–636 | |
| PEDVR | Reverse | Conventional-PCR | 1050–1068 | |
| PEDV-DP1 | Forward | Detect-PCR | ||
| PEDV-DP2 | Reverse | Detect-PCR | ||
| Probe 1 | Hybridization | 76–101 | ||
| Probe 2 | Hybridization | 626–651 | ||
| Probe 3 | Hybridization | 6234–6259 | ||
| Probe 4 | Hybridization | 6784–6809 | ||
| Probe 5 | Hybridization | 7046–7071 | ||
| Probe 6 | Hybridization | 7525–7550 | ||
| Probe 7 | Hybridization | 7324–7349 | ||
| Probe 8 | Hybridization | 7858–7883 | ||
| Probe 9 | Hybridization | 7382–7407 | ||
| Probe 10 | Hybridization | 7936–7961 | ||
| Probe 11 | Hybridization | 8258–8283 | ||
| Probe 12 | Hybridization | 8775–8800 | ||
| Probe 13 | Hybridization | 9234–9259 | ||
| Probe 14 | Hybridization | 9762–9787 | ||
| Probe 15 | Hybridization | 10976–11001 | ||
| Probe 16 | Hybridization | 11496–11521 |
Selected oligos used in this study.
| Label | Orientation | Assay | Sequence (5′–3′) | Position |
|---|---|---|---|---|
| Oligo 1 | Hybridization/Amplification | 76–101 | ||
| Oligo 2 | Hybridization/Amplification | 626–651 | ||
| Oligo 3 | Hybridization/Amplification | 6234–6259 | ||
| Oligo 4 | Hybridization/Amplification | 6784–6809 | ||
| Oligo 5 | Hybridization/Amplification | 7046–7071 | ||
| Oligo 6 | Hybridization/Amplification | 7525–7550 | ||
| Oligo 7 | Hybridization/Amplification | 7324–7349 | ||
| Oligo 8 | Hybridization/Amplification | 7858–7883 | ||
| Oligo 9 | Hybridization/Amplification | 7382–7407 | ||
| Oligo 10 | Hybridization/Amplification | 7936–7961 | ||
| Oligo 11 | Hybridization/Amplification | 8258–8283 | ||
| Oligo 12 | Hybridization/Amplification | 8775–8800 | ||
| Oligo 13 | Hybridization/Amplification | 9234–9259 | ||
| Oligo 14 | Hybridization/Amplification | 9762–9787 | ||
| Oligo 15 | Hybridization/Amplification | 10976–11001 | ||
| Oligo 16 | Hybridization/Amplification | 11496–11521 |
Fig 1Schematic of detecting PEDV from fecal samples using functionalized nanoparticles.
Fig 2Comparison of different functionalized MMPs and AuNPs.
(A) Probes-coated magnetic microparticles MMPs-p1 to p16 were incubated with RNA of PEDV in hybridization buffer at 40°C for 30 minutes, followed by rinsing and magnetic separation. Then the MMPs-RNA complexes were subjected to PEDV-specific RT-PCR. M: Trans 2K Plus DNA Marker; 1: p1; 2: p2; 3: p3; 4: p4; 5: p5; 6: p6; 7: p7; 8: p8; 9: p9; 10: p10; 11: p11; 12: p12; 13: p13; 14: p14; 15: p15; 16: p16. (B) PEDV RNA was incubated with oligo1 to 16 coated Au-NPs at 50°C for 40 minuts. Then the complexes were washed and precipitated by centrifugation, followed by reverse transcription and PEDV specific RT-PCR detection. M: Trans 2K Plus DNA Marker; 1: oligo1; 2: oligo2; 3:oligo3; 4: oligo4; 5: oligo5; 6: oligo6; 7: oligo7; 8: oligo8; 9: oligo9; 10: oligo10; 11: oligo11; 12: oligo12; 13: oligo13; 14: oligo14; 15: oligo15; 16: oligo16.
Fig 3Analysis of the sensitivity of functionalized nanoparticles-based PCR assay for PEDV.
(A) Serial dilutions of PEDV fecal samples were detected by functionalized nanoparticles-based PCR assay for PEDV. (B) Serial dilutions of PEDV fecal samples were detected by conventional RT-PCR.
Fig 4Analysis of the reproducibility and specificity of functionalized nanoparticles-based PCR assay for PEDV.
(A) Three different concentrations of PEDV samples were detected by functionalized nanoparticles-based PCR assay for PEDV in triplicates and in three independent runs. Lane M: Trans 2K Plus DNA Marker; lane 1–3: 104; lane 4–6: 103; lane 7–9: 102; lane10: negative samples. (B) PCV2, PPV, TGEV, CSFV, PRRSV and stools collected from healthy swine were detected by functionalized nanoparticles-based PCR assay for PEDV as control. Lane M: Trans 2K Plus DNA Marker; lane 1: PEDV; lane 2: the stools of healthy swine; lane 3: PCV2; lane 4: PPV; lane 5: TGEV; lane 6: CSFV; lane 7: PRRSV.
Comparison of the detection rate of PEDV infected preclinical fecal samples by conventional RT-PCR, functionalized nanoparticles-based PCR and SYBR Green real-time RT-PCR assay.
| Conventional RT-PCR | Functionalized nanoparticles-based PCR | SYBR Green real-time RT-PCR | |
|---|---|---|---|
| Total number of tested samples | 153 | 153 | 153 |
| Number of positive samples | 9 | 47 | 27 |
| Number of negative samples | 144 | 106 | 126 |
| Positive rate (%) | 5.88 | 30.72 | 17.65 |
Fig 5Detection of preclinical samples using real-time RT-PCR and functionalized nanoparticles-based PCR assay for PEDV.
(A) SYBR Green real-time RT-PCR assay detected the all of positive samples and part negative samples identified by functionalized nanoparticles-based PCR assay. The figure showed all of positive samples and part negative samples identified by real-time RT-PCR for PEDV. (B) Agarose gel electrophoresis analysis of the relative viral load levels of 20 selected PEDV positive preclinical fecal samples identified by functionalized nanoparticles-based PCR assay specific for PEDV. Lane M: Trans 2K Plus DNA Marker; lane 1–20: preclinical fecal specimens; lane 21: 104 Standards; lane 22: 103 Standards; lane 23: 102 Standards; lane 24: negative samples.